Morgan Stanley Forecasts Strong Price Appreciation for Biogen (NASDAQ:BIIB) Stock

Biogen (NASDAQ:BIIB) had its price objective boosted by stock analysts at Morgan Stanley from $206.00 to $224.00 in a report released on Thursday,Benzinga reports. The firm presently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target would suggest a potential upside of 12.75% from the company’s previous close.

BIIB has been the subject of a number of other research reports. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a report on Saturday, May 2nd. Guggenheim boosted their price target on shares of Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. boosted their price target on shares of Biogen from $175.00 to $185.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating and set a $225.00 price target (up from $214.00) on shares of Biogen in a report on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $217.37.

Biogen Trading Up 1.6%

Shares of BIIB stock opened at $198.67 on Thursday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The stock has a market capitalization of $29.33 billion, a P/E ratio of 21.32 and a beta of 0.20. The company has a 50 day moving average price of $190.05 and a 200 day moving average price of $184.70. Biogen has a fifty-two week low of $121.05 and a fifty-two week high of $205.97.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities research analysts predict that Biogen will post 13.89 EPS for the current fiscal year.

Institutional Trading of Biogen

Several institutional investors have recently modified their holdings of the stock. Parallel Advisors LLC lifted its position in shares of Biogen by 1.5% during the 1st quarter. Parallel Advisors LLC now owns 4,367 shares of the biotechnology company’s stock worth $801,000 after buying an additional 65 shares during the last quarter. Caerus Investment Advisors LLC lifted its position in shares of Biogen by 5.0% during the 1st quarter. Caerus Investment Advisors LLC now owns 2,801 shares of the biotechnology company’s stock worth $514,000 after buying an additional 134 shares during the last quarter. Financial Solutions Advisory Group Inc. purchased a new stake in shares of Biogen during the 1st quarter worth approximately $252,000. Glenmede Trust Co. NA lifted its position in shares of Biogen by 17.5% during the 1st quarter. Glenmede Trust Co. NA now owns 11,652 shares of the biotechnology company’s stock worth $2,136,000 after buying an additional 1,733 shares during the last quarter. Finally, Groupama Asset Managment lifted its position in shares of Biogen by 3.8% during the 1st quarter. Groupama Asset Managment now owns 8,753 shares of the biotechnology company’s stock worth $1,605,000 after buying an additional 322 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said it will acquire private biotech RayThera for up to $1 billion, adding multiple immunology assets and a lead program that is expected to enter Phase 1 development. Investors are viewing the deal as a long-term growth move that could deepen Biogen’s presence in immunology. Biogen to acquire RayThera for $1 billion
• Positive Sentiment: Needham maintained a Buy rating on Biogen with a $255 price target, suggesting the RayThera acquisition could improve the company’s immunology pipeline and support longer-term upside. Biogen Rated Buy as RayThera Acquisition Bolsters Immunology Pipeline and Long-Term Growth Prospects
• Neutral Sentiment: Biogen’s acquisition announcement was broadly repeated across several outlets, reinforcing the market’s focus on the strategic rationale rather than adding new information. Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
• Negative Sentiment: A Pomerantz LLP investor investigation into Biogen may create overhang and raise headline risk, even though no outcome has been determined. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB
• Negative Sentiment: Biogen Canada also reported disappointment after pCPA negotiations for SKYCLARYS ended without an agreement, which could modestly pressure expectations for that product’s commercial expansion in Canada. Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for SKYCLARYS™

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.